Expertise in
8
conditions

Romain Altwegg

CHU Montpellier
Montpellier, FR 
Expertise in
8
conditions
CHU Montpellier
Montpellier, FR 
OverviewLocationsClinical Research

Overview

Romain Altwegg practices in Montpellier, France. Mr. Altwegg is highly rated in 8 conditions, according to our data. His top areas of expertise are Viral Gastroenteritis, Colitis, Ulcerative Colitis, Small Bowel Resection, and Endoscopy.

His clinical research consists of co-authoring 96 peer reviewed articles and participating in 16 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

CHU Montpellier
Montpellier, France
Other Locations
Montfermeil, France
CHU of Saint Etienne
Saint-etienne-de-valoux, France
Hotel Dieu
Nantes, France
CHU Bordeaux
Bordeaux, France
CHU Lyon Sud
Pierre-la-treiche, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
Enrollment Status: Active_not_recruiting
Publish Date: October 10, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
VERDICT: In actiVE Ulcerative Colitis, a RanDomIzed Controlled Trial for Determination of the Optimal Treatment Target
VERDICT: In actiVE Ulcerative Colitis, a RanDomIzed Controlled Trial for Determination of the Optimal Treatment Target
Enrollment Status: Active_not_recruiting
Publish Date: September 11, 2025
Intervention Type: Biological
Study Drug: Vedolizumab
Study Phase: Phase 4
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn's Disease
A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn's Disease
Enrollment Status: Active_not_recruiting
Publish Date: April 18, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
Prospective, Controlled, Randomized, Multicentered, Open-label Study, Comparing 2 Modalities of Follow-up of Patients With Crohn's Disease, Postoperatively Treated With Adalimumab (Immunomonitoring vs Standard Follow-up)
Prospective, Controlled, Randomized, Multicentered, Open-label Study, Comparing 2 Modalities of Follow-up of Patients With Crohn's Disease, Postoperatively Treated With Adalimumab (Immunomonitoring vs Standard Follow-up)
Enrollment Status: Terminated
Publish Date: January 21, 2025
Intervention Type: Other
Study Drug: Adalimumab
Study Phase: Not Applicable
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drugs: Mirikizumab, Ustekinumab
Study Phase: Phase 3
USTekinumab in Fistulising Perianal Crohn's Disease (CD): The USTAP CD Study
USTekinumab in Fistulising Perianal Crohn's Disease (CD): The USTAP CD Study
Enrollment Status: Active_not_recruiting
Publish Date: July 22, 2024
Intervention Type: Drug
Study Drug: Ustekinumab
Study Phase: Phase 4
Impact of Anti-cytomegalovirus (Valganciclovir) Treatment in the Management of Relapsing Ulcerative Colitis (UC) Requiring Vedolizumab Therapy: a Randomized Clinical Trial Comparing a Strategy With or Without Antiviral Therapy.
Impact of Anti-cytomegalovirus (Valganciclovir) Treatment in the Management of Relapsing Ulcerative Colitis (UC) Requiring Vedolizumab Therapy: a Randomized Clinical Trial Comparing a Strategy With or Without Antiviral Therapy.
Enrollment Status: Terminated
Publish Date: April 10, 2024
Intervention Type: Drug
Study Drug: Valganciclovir
Study Phase: Phase 3
Changing the coUrse of cRohn's Disease With an Early Use of Adalimumab
Changing the coUrse of cRohn's Disease With an Early Use of Adalimumab
Enrollment Status: Unknown
Publish Date: May 31, 2023
Intervention Type: Drug
Study Drug: Adalimumab
Study Phase: Phase 4
Intensive Treatment to Reach the Target With Golimumab in ulcErative coliTis- In-TARGET
Intensive Treatment to Reach the Target With Golimumab in ulcErative coliTis- In-TARGET
Enrollment Status: Completed
Publish Date: May 31, 2023
Intervention Type: Drug
Study Drug: Golimumab
Study Phase: Phase 4
A Randomized, Multicenter Open Label Study Comparing Early Administration of Azathioprine Plus Infliximab to Corticosteroids Plus Azathioprine for Acute Severe Colitis
A Randomized, Multicenter Open Label Study Comparing Early Administration of Azathioprine Plus Infliximab to Corticosteroids Plus Azathioprine for Acute Severe Colitis
Enrollment Status: Completed
Publish Date: May 31, 2023
Intervention Type: Drug
Study Drugs: Azathioprine, Infliximab, Prednisolone, Hydrocortisone
Study Phase: Phase 4
A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy
A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy
Enrollment Status: Completed
Publish Date: August 03, 2022
Intervention Type: Drug
Study Drugs: Infliximab, Azathioprine, Mercaptopurine, Methotrexate
Study Phase: Phase 4
A Multicentre Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Safety, Tolerability, Efficacy, Dose-response, Pharmacokinetics and Pharmacodynamics of Repeat Dosing of an Anti-LAG3 Cell Depleting Monoclonal Antibody (GSK2831781) in Patients With Active Ulcerative Colitis
A Multicentre Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Safety, Tolerability, Efficacy, Dose-response, Pharmacokinetics and Pharmacodynamics of Repeat Dosing of an Anti-LAG3 Cell Depleting Monoclonal Antibody (GSK2831781) in Patients With Active Ulcerative Colitis
Enrollment Status: Terminated
Publish Date: April 27, 2022
Intervention Type: Drug
Study Drug: GSK2831781
Study Phase: Phase 2
Pharmacokinetic and Pharmacodynamic Study of Golimumab in Ulcerative Colitis (UC) Patients With Loss of Response (LOR) Followed by Dose Optimization
Pharmacokinetic and Pharmacodynamic Study of Golimumab in Ulcerative Colitis (UC) Patients With Loss of Response (LOR) Followed by Dose Optimization
Enrollment Status: Completed
Publish Date: March 14, 2022
Intervention Type: Drug, Diagnostic test, Biological
Study Drug: Golimumab
Study Phase: Phase 2
Identification of Composite Clinical and Lab Scores Associated With a Favorable Clinical Response With Thiopurines in Patients With IBD (Inflammatory Bowel Disease): an International Clinical Trial
Identification of Composite Clinical and Lab Scores Associated With a Favorable Clinical Response With Thiopurines in Patients With IBD (Inflammatory Bowel Disease): an International Clinical Trial
Enrollment Status: Completed
Publish Date: August 22, 2017
Intervention Type: Other
View 15 Less Clinical Trials

96 Total Publications

Subcutaneous vedolizumab dose intensification in inflammatory bowel disease patients: the OPTI-VEDO multicenter study from the GETAID.
Subcutaneous vedolizumab dose intensification in inflammatory bowel disease patients: the OPTI-VEDO multicenter study from the GETAID.
Journal: Journal of Crohn's & colitis
Published: September 10, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Altwegg's expertise for a condition
ConditionClose
    View All 14 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile